norstella-logo-white
Contact us

Insights

Keep up with the latest insights from Norstella and its market-leading brands.

News

Press Releases | Mar. 18, 2025

Norstella named to Fast Company’s annual list of the world’s most innovative companies of 2025

New York – March 18, 2025 – Norstella, a leading global provider of pharma intelligence solutions, is proud to have been named to Fast Company’s prestigious list of the World’s Most Innovative Companies of 2025. This year’s list shines a spotlight on businesses that are shaping industry and culture through their innovations to set new standards and achieve remarkable milestones in all sectors of the economy. Read more
Press Releases | Feb. 05, 2025

Neelesh Sali named Managing Director & Country Head of Norstella India

New York – February 5, 2025 – Norstella, a leading global provider of pharma intelligence solutions, is proud to announce the appointment of Neelesh Sali as Managing Director and Country Head for India. With over 30 years of leadership experience driving operational excellence and scaling global organizations, Neelesh brings a proven track record of transformative growth and innovation to Norstella’s mission of smoothing the path to life-saving treatments. Read more
Press Releases | Feb. 04, 2025

NorstellaLinQ data source added to Atropos Evidence™ Network, scoring in the top decile for data quality on Real World Fitness Score®

Palo Alto, CA – February 4, 2025 – Atropos Health, the pioneer in translating real-world clinical data into high-quality personalized real-world evidence (RWE) for care, announces the availability of an initial dataset from NorstellaLinQ on the Atropos Evidence Network. NorstellaLinQ, built by Norstella, one of the largest global pharma intelligence solution providers, is the first and only fully integrated data asset combining real-world data (RWD) and proprietary intelligence from the most trusted brands in the industry, paving the way for breakthroughs in drug development and commercialization. Read more
In the news | Jan. 16, 2025

NorstellaLinQ in the news

Since introducing NorstellaLinQ, biopharma’s first fully integrated data asset combining RWD and our wealth of proprietary information, we have been busily meeting with customers to explain how it can support their workflows. It is not only our pharma partners that have taken notice, but the trade media has also wanted to learn more. Suzanne Caruso, General Manager for Clinical & Regulatory at Norstella, met with reporters from STAT and Precision Medicine Online to explain. Read more
In the news | Nov. 20, 2024

Norstella recognized as company of the year in the 2024 BIG Awards for Business

Norstella is pleased to announce that the Business Intelligence Group has selected the company as a winner in its hotly contested "Company of the Year" category. This recognition, part of the broader 2024 BIG Awards for Business, celebrates those companies, products, and leaders making a significant impact by reshaping their industries and setting new standards for success. For Norstella, it signifies the considerable progress we are making against our mission to to smooth the path to lifesaving therapies for patients and providers. Read more
Press Releases | Oct. 08, 2024

Norstella introduces NorstellaLinQ, the biopharma industry’s first fully integrated data asset

NEW YORK – October 8, 2024 - Today, Norstella unveiled NorstellaLinQ, the biopharma industry’s first and only fully integrated data asset combining both real-world data (RWD) — including open and closed claims, lab results and structured and unstructured electronic medical records (EMR) — with Norstella’s proprietary forecasting, clinical, regulatory, payer, coverage and commercial intelligence data. Read more
Press Releases | Sep. 05, 2024

Panalgo introduces IHD Cloud, a transformative solution for RWE data and analytics centralization

Boston, MA - Sept. 5, 2024 - Panalgo, a Norstella company committed to revolutionizing healthcare data analytics, is announcing the launch of IHD Cloud, a cutting-edge solution that will transform how organizations manage and use real-world data (RWD) to generate real-world evidence (RWE). Powered by Amazon Web Services (AWS), IHD Cloud offers a scalable and flexible platform to centralize data and technology, driving meaningful and timely insights for any evidence generating organization. Read more
Press Releases | Aug. 13, 2024

In a first for pharma, Citeline SmartSolutions take AI to new levels, optimizing clinical trial planning and site selection

NEW YORK – Aug. 13, 2024 – Citeline, a leader in intelligence solutions for the life sciences industry, has launched two new products — Protocol SmartDesign and Investigator SmartSelect — in its Citeline SmartSolutions suite accelerating the path from pipeline to patient. Citeline SmartSolutions, an industry first, enables users to design and conduct more predictable trials by connecting the robust data assets already trusted by over 3,000 Citeline customers. Read more
Press Releases | Jun. 17, 2024

Atropos Health partners with Norstella to expand the Atropos Evidence™ Network and structured clinical trial intelligence

BOSTON – June 17, 2024 – Norstella, one of the largest global pharma intelligence solution providers, today announced a strategic partnership with Atropos Health, the pioneer in translating real-world clinical data into high-quality personalized real-world evidence for care. This collaboration follows Atropos Health’s recent announcement of $33 million in Series B funding, furthering its expansion into life sciences. Read more
Press Releases | Jan. 10, 2024

Evaluate, a Norstella company, announces acquisition of J+D Forecasting

January 8, 2024, London, UK and Boston, MA – Evaluate, a Norstella company, announced today the acquisition of J+D Forecasting, a leading provider of forecasting solutions for the pharmaceutical industry. Read more
Press Releases | Dec. 04, 2023

MMIT wins Titan Health Award for healthcare innovation

December 4, 2023, Yardley, PA – MMIT, a Norstella company and the trusted go-to-market partner for overcoming barriers to patient access, is excited to announce that its Patient Access Analytics solution has won a Titan Health Award, which celebrates and recognizes extraordinary achievements in healthcare advertising and marketing. Read more
Press Releases | May. 16, 2023

Industry veteran Fred Hassan joins the board of Norstella

Norstella, a leader in helping patients gain access to life-saving therapies by navigating the complexities at each step of the drug development life cycle, is pleased to announce that Fred Hassan has joined its board of directors. Hassan brings a wealth of experience and expertise in healthcare, having served as CEO of several major pharmaceutical companies and as a board member of numerous healthcare organizations. He has held senior leadership roles at some of the world's most prominent organizations, including Schering-Plough, Pharmacia Corporation, and Bausch & Lomb. Read more
Press Releases | Apr. 04, 2023

TriNetX and Clinerion unite as TriNetX and Norstella announce strategic partnership

Cambridge, MA, April 4, 2023 — TriNetX, the global network of healthcare organizations driving real-world research to accelerate the development of novel therapies, and Norstella, the leading pharmaceuticals solutions provider, today announced a multi-faceted strategic partnership. As part of this exciting partnership, TriNetX will acquire Norstella’s Clinerion Ltd. subsidiary, expanding the growth of the world’s leading research network for real world data (RWD). Read more
Press Releases | Mar. 30, 2023

Citeline launches TrialScope intelligence, meeting the growing complexities of clinical trial disclosure

Clinical trial disclosure compliance is challenging, whether a sponsor is registering five trials or 500 trials. Compounding the complexity is the fact that no global standards exist for disclosure. With ever-changing global regulations, new requirements on the rise and the threat of monetary penalties, study sponsors are feeling the pressure to maintain compliance, minimize risk and safeguard their brand reputation. Read more
In the news | Mar. 07, 2023

How robust data technology is transforming the design and execution of viable clinical trials

While incorporating real-world data (RWD) and real-world evidence (RWE) across the drug development lifecycle is getting a lot of attention, the application of such insights gleaned from rigorous analysis to the design and execution of clinical trials has yet to be widely adopted, despite its potential to address some of these persistent challenges. Read more
In the news | Jan. 08, 2023

What do you view as the most disruptive or transformational technology or development on the horizon?

Norstella CEO, Mike Gallup, weighs in on the most disruptive / transformational technology on the horizon in a recent pharma’s almanac piece. “As regulators and payers look for new information to guide their decision-making, real-world data and evidence are poised to play a transformative role in not only getting drugs to market quickly, but also ensuring that patients can access them.” Read more
Press Releases | Dec. 09, 2022

Exclusive AIS Health data outlines 2021 compensation for health insurer CEOs

Washington, DC, Dec. 9, 2022 — In AIS Health’s annual roundup of health insurer executive compensation data, four newly public startup insurers stand out. But the stock awards that are largely driving their eye-popping total compensation figures — such as Clover Health Investments Corp. CEO Vivek Garipalli’s $390 million or Bright Health Group, Inc. CEO Mike Mikan’s $181 million — are based in part on the firms’ initial public offering (IPO) stock valuations, which were many times higher than what their shares are now worth. Read more
In the news | Nov. 14, 2022

Industry leaders offer reflections on 2022 and predictions for 2023

The COVID-19 pandemic has continued to evolve, forcing companies to adapt to a constantly changing landscape filled with fluid consumer expectations. Meanwhile, several other key healthcare-related trends have bubbled to the surface over that period. Read more
In the news | Nov. 14, 2022

What can we expect in pharma in 2023?

Drug pricing, CMS getting negotiating power for drug purchasing, vaccines, clinical trials, artificial intelligence, and Pharmacists becoming care givers. These are the highlights of 2022, what do the experts say we will see in 2023? We rounded up some experts and asked them just that. And join us for the next few weeks as we look at what we might see in 2023. Read more
In the news | Nov. 14, 2022

The 2023 PharmaVoice crystal ball: peering into the future of life sciences

For the 2023 PharmaVoice Year in Preview, we zeroed in on six key trends: clinical trial diversity, disruptive tech, innovation, talent management, patient engagement and leading through uncertain times. Here, we’ve asked industry execs to look into their crystal balls and tell us about anything they see coming. Read more
Press Releases | Nov. 01, 2022

Citeline and Norstella complete merger to form a $5 billion global pharmaceutical technology company

Nov. 1, 2022 – Norstella, a global leader with end-to-end solutions that smooth access to life-saving therapies for patients, has announced the completion of its merger with Citeline (formerly Pharma Intelligence), a leader in the clinical trial intelligence space. At deal close, the $5 billion global company is now one of the world’s largest pharma intelligence solutions providers on the market, with more than 1,600 employees across the five brands that make up Norstella: Evaluate, MMIT, Panalgo, The Dedham Group, and now Citeline. Read more
Press Releases | Jun. 28, 2022

Citeline and Norstella unite to offer life sciences clients a full suite of commercial and clinical solutions

June 28, 2022 – Norstella, an organization that helps life sciences companies navigate the complexities of the drug life cycle, and Citeline (formerly Pharma Intelligence)—a leading provider of specialist intelligence, data and software for clinical trials, drug development and regulatory compliance—have announced an agreement to merge the companies. Read more
Press Releases | Jun. 23, 2022

MMIT announces winners of the Q1 2022 Patient Access Awards

June 23, 2022, Yardley, PA – Managed Markets Insight & Technology (MMIT)—the trusted go-to-market partner for overcoming barriers to patient access—has launched the inaugural Patient Access Awards to honor pharmaceutical manufacturers committed to improving patient access to life-saving therapies. Read more
In the news | Jun. 22, 2022

Merger creates $5 billion pharma technology company

Norstella and Citeline (formerly Pharma Intelligence) have merged to form a $5 billion global company, one of the largest pharma intelligence solutions providers on the market. Read more
In the news | Jun. 22, 2022

Norstella, Citeline merge to create $5bn pharma tech firm

Citeline and Norstella have completed a merger, first announced in June, to create one of the largest players in the pharmaceutical intelligence category. Read more
In the news | Jun. 22, 2022

Norstella completes acquisition of Citeline to form $5B pharma intelligence group

Although financial terms weren’t disclosed, Norstella estimates that it is now a $5 billion player in the market, the company said in a Nov. 1 press release. The acquisition was first announced in June. Read more
In the news | Jun. 22, 2022

Norstella completes merger with Citeline to form $5B pharma tech company

The combined company has more than 1,500 employees worldwide, including about 200 in the Philadelphia region. Read more
In the news | Jun. 22, 2022

Citeline, Norstella complete $5B merger

Citeline and Norstella announced the completion of their $5 billion merger Tuesday morning. The deal, first announced in late June, creates one of the world’s largest pharmaceutical intelligence solutions providers. The combined company has $5 billion and 1,600 employees. Citeline will join four other brands, Evaluate, MMIT, Panalgo and The Dedham Group, as part of Norstella. Read more
Press Releases | May. 09, 2022

MMIT announces the winners of the seventh-annual specialty pharmacy Patient Choice Awards

May 9, 2022, Yardley, PA – Managed Markets Insight & Technology (MMIT)—the trusted go-to-market partner for overcoming barriers to patient access—has announced the winners of the seventh-annual Specialty Pharmacy Patient Choice Awards.  Each year, MMIT hosts the Patient Choice Awards to honor specialty pharmacies that provide best-in-class customer satisfaction and overall patient care within four categories: Payer/PBM, Hospital and Health System, Independent and Retail. Read more
Press Releases | May. 03, 2022

Four prominent pharmaceutical solutions providers launch Norstella to drive innovation and get patients access to life-saving therapies faster

May 3, 2022 – Creating a hub for rapid innovation, four prominent pharmaceutical solutions providers—Evaluate, MMIT, Panalgo and The Dedham Group—are thrilled to announce the launch of Norstella. Read more
Press Releases | Feb. 17, 2022

MMIT announces game-changing solution for life sciences companies

Feb. 17, 2022, Yardley, PA – Following the acquisition of healthcare analytics company Panalgo in September 2021, Managed Markets Insight & Technology (MMIT) has announced the launch of Patient Access Analytics Read more
Press Releases | Sep. 28, 2021

MMIT/Evaluate acquire Panalgo

MMIT/Evaluate Acquire Panalgo to Bring Speed and Trust to Pharma Analytics and Decision-Making The move will result in a disruptive, market-leading analytics platform that provides on-demand insights across dozens of normalized real-world evidence and market access data sets that support decision-making from pipeline to prescription September 28, 2021, Yardley, PA — Managed Markets Insight & Technology (MMIT) and […] Read more
Press Releases | Aug. 20, 2021

MMIT and Evaluate

MMIT and Evaluate Join Forces to Offer an End-to-End View of the Pharmaceutical Market Landscape By combining their technology, data and expertise, MMIT and Evaluate will become a $1.6 billion global pharma commercial intelligence provider August 20, 2021, Yardley, PA — Managed Markets Insight & Technology (MMIT), LLC, the trusted go-to-market partner solely focused on solving the “what […] Read more
Press Releases | Apr. 27, 2021

MMIT & The Dedham Group unite to smooth access to therapy

The combined data, technologies and expertise of both organizations will positively impact patient access to life saving treatments April 27, 2021, Yardley, PA – Managed Markets Insight & Technology, LLC. (MMIT), the trusted go-to-market partner solely focused on solving the “what and why” of market access—so that patients don’t face delays when trying to access lifesaving […] Read more

Insights

Article | Apr. 24, 2025

The patient availability conundrum

Despite tremendous scientific and medical advances, the economics of investing in drug research and development are challenging. The long-term trend suggests increasing R&D costs, lengthy development timelines, and high rates of failure. There are many factors that influence a positive outcome, from individual drug development decisions up to wider regulatory frameworks, all of which are […] Read more
Article | Apr. 16, 2025

The resurgence of mental health drug development and why it matters

After decades of stagnation, the field of mental health drug development is finally seeing some movement. A wave of innovation, bolstered by new science, shifting public attitudes, and landmark regulatory moments, is transforming how we understand and treat mental health conditions. “It’s like we’ve been playing the same song on repeat,” says Emma Wille, a […] Read more
Article | Mar. 27, 2025

How unstructured EMR data helps pharma find patients

As therapies have become more complex, pharma companies are now challenged to achieve precision targeting within a much tighter timeframe. While claims data is readily available, one of its key limitations is the lack of timeliness. Many manufacturers now rely on specialized lab data—from imaging results to genetic testing and genomics—to identify eligible patients and […] Read more
Article | Mar. 10, 2025

Connecting the dots with NorstellaLinQ

Norstella’s VP of thought leadership, Daniel Chancellor, was invited to share his perspectives on the proliferation of data with the leading publication The Medicine Maker. The timing was perfect, coming shortly after we launched NorstellaLinQ, the biopharma industry’s first fully integrated data asset. The article explores various themes such as abundance, the importance of data […] Read more
Article | Mar. 04, 2025

Spotlight on South Korea: Innovation, clinical trials, and market trends shaping 2025

In a series exploring trends across the APAC region, Norstella’s subject matter experts from key biopharma hubs delve into this year’s standout developments and share their outlook for 2025. South Korea has firmly established itself as a global biopharma innovation hub, ranking third worldwide in new drug discoveries. According to Citeline’s Pharmaprojects database, South Korean […] Read more
Article | Feb. 27, 2025

The ‘Doing now what patients need next’ portfolio approach

Among all the corporate presentations at the 2025 J.P. Morgan Healthcare Conference, one small graphic from Roche (page 7), along with its purpose statement of “Doing now what patients need next”, stood out. The analysis was of how Roche’s product portfolio stacks up against global disease burden, both now and 10 years in the future. […] Read more
Article | Feb. 13, 2025

Assessing current AI trends in drug development: Operational efficiency and overcoming challenges (part 2)

Artificial intelligence (AI) has shifted from experimental projects to a valuable pharmaceutical research and development (R&D) asset. While the pace of adoption varies across the industry, AI is enabling organizations to address inefficiencies, reduce timelines, and improve decision-making at critical drug development stages. Building on the insights from part 1, which highlighted how companies are […] Read more
Article | Jan. 28, 2025

Biopharma’s R&D engine and the importance of looking east

One of the main topics of conversation at the beginning of 2025 is how pharma companies should build their pipelines and the rising role that China is playing. A widely-cited report from Stifel showed that 30% of large pharma’s licensing deals now involve a Chinese biotech. This shows the growing interest in partnering in the […] Read more
Article | Jan. 23, 2025

Spotlight on India: A booming part of the global ecosystem

In a series exploring trends across the APAC region, Norstella’s subject matter experts from key biopharma hubs delve into last year’s standout developments and share their outlook for 2025. Andrew Warmington, Manufacturing Editor at Citeline, spoke to Anju Ghangurde, Executive Editor, APAC, Citeline, and Vibha Ravi, Senior Editor, APAC, Citeline. How would you describe the […] Read more
Article | Dec. 19, 2024

Spotlight on Japan: A supportive government but market share declines

In a series exploring trends across the APAC region, Norstella’s subject matter experts from key biopharma hubs delve into this year’s standout developments and share their outlook for 2025. Andrew Warmington, Manufacturing Editor at Citeline, spoke to Ian Haydock, Editor-In-Chief, and Lisa Takagi, Managing Editor at Insights in the APAC region, about key developments this […] Read more
Article | Dec. 17, 2024

Harnessing the power of RWE to improve drug development

Real-world evidence (RWE) is becoming increasingly important in driving pharmaceutical innovations, as it helps researchers to understand the settings in which a drug, medical device, or other treatment is applied, such as innovation, care patterns, and disease burden in populations. Through the systematic analysis of real-world data (RWD), RWE can support clinical trial evidence, particularly […] Read more
Article | Dec. 05, 2024

Harnessing lab data to speed time to treatment

In recent years, pharma companies have begun to embrace lab data as a richly rewarding dataset for a whole host of purposes, including trial enrollment and site identification, patient monitoring and disease progression, and commercial targeting and market access insights. Along with test orders, values, and results, deidentified lab data includes a wealth of information, […] Read more
Article | Nov. 28, 2024

Spotlight on China: A dominant player in the clinical trial landscape

In a series exploring trends across the APAC region, Norstella’s subject matter experts from key biopharma hubs delve into this year’s standout developments and share their outlook for 2025. China’s booming clinical trial landscape continues to grow and diversify with greater investment from Big Pharma in addition to new promising modalities at play. In our […] Read more
Article | Oct. 31, 2024

Assessing current AI trends in drug development: Adoption and transformation (part 1)

Pharmaceutical R&D is undergoing significant changes. The need to accelerate drug development and enhance decision-making has placed artificial intelligence (AI) at the core of industry transformation. According to Norstella’s State of the Industry AI survey, 2024, 81% of organizations already use AI in at least one development program. This reveals that AI is rapidly becoming […] Read more
In the news | Oct. 15, 2024

Norstella rolls out NorstellaLinQ data platform

Norstella LinQ establishes a throughline between the company’s various subsidiaries, utilizing capabilities from Citeline, Evaluate, MMIT, Panalgo and The Dedham Group. Norstella debuted its NorstellaLinQ data platform on Tuesday, an offering from the pharmaceutical intelligence solutions provider that aggregates and cleans real-world data from various sources to provide high quality, comprehensive patient information. Utilizing Norstella’s […] Read more
Article | Oct. 15, 2024

The practice-changing drugs that will land in 2025

2025 promises to represent another rich year of progress. A wealth of new therapies are set to successfully graduate from the pipeline. Within this cohort are a mixture of therapeutic areas, drug classes, first-time approvals, label expansions, and most importantly treatments that will meaningfully change how diseases are treated. This article provides a snapshot of […] Read more
Article | Oct. 01, 2024

Pharma’s future: More with less

2023 saw the biopharmaceutical industry spend a record $300bn on R&D activities, reinvesting approximately 30% of prescription revenues to secure the next generation of therapies. Yet, recent weeks have seen falling valuations and stark anecdotes from contract research organizations as their main client base – large pharma companies – have tightened the belt on early […] Read more
Article | Sep. 09, 2024

Pharma outlook: From uncertainty to predictability

Change is the only constant in the pharmaceuticals industry. There have been many paradigm shifts driven by specific therapies, like AIDS in the 1990s and the COVID-19 vaccine in 2020, and some believe that the recent rise of obesity and diabetes drugs to be potentially the biggest of all. That said, it may be that […] Read more
Article | Aug. 07, 2024

The evolution of cell therapy to address unmet medical needs

Cell and gene therapies (C&GTs) enjoyed “a landmark close” to 2023 and continued its momentum in Q1 2024 with “several notable approvals and strong growth in all stages of clinical development”, according to the latest quarterly Gene, Cell & RNA Therapy Landscape Report by Citeline in association with the American Society of Cell & Gene […] Read more
Article | Jul. 30, 2024

2024 FDA diversity guidance: What it means and how it could impact future clinical trial outcomes

The US Food and Drug Administration (FDA) released a diversity-focused draft guidance entitled “Diversity Action Plans to Improve Enrollment of Participants from Underrepresented Populations in Clinical Studies” on June 26, 2024. I sat down with Lya Rebelo, commercial enablement manager at Citeline, to discuss the future impact of this long-awaited guidance, how it differs from […] Read more
Ebook | Jul. 08, 2024

How Norstella is embedding artificial intelligence to improve pipeline to patient decision-making

In this white paper, Norstella describes its vision for the integration of artificial intelligence with its industry-leading data and advisory services. At each step from pipeline to patient, Norstella is embedding AI to create the next generation of solutions. These will help biopharma professionals to better contextualize their challenges, predict how scenarios will play out, […] Read more
Article | Jul. 03, 2024

How can small biopharma use end-to-end CDMO partnerships to accelerate development?

There is growing evidence that pharma and biotech companies in general, and small biopharmas in particular, are increasingly looking at ‘end-to-end’ partnerships with contract development and manufacturing organizations (CDMOs) for the outsourcing of drug development. It is also clear that a growing number of CDMOs are adding to their range of capabilities in order to […] Read more
Video | Jun. 27, 2024

Class of 2024: Norstella intern yearbook

As members of a vastly expanding industry, it is our job to empower other problem-solvers and pioneers who will one day become key change-drivers leading the way to a brighter future. Norstella has always been committed to championing new ideas that come from diverse pools of talent, which is why we are thrilled to host our […] Read more
Report | Jun. 17, 2024

Putting the patient first: Advancing biopharma innovation and industry transformation

Norstella is driven by its mission: Helping patients gain access to life-saving therapies by transforming the drug development journey. Norstella is working to fulfill this mission in a challenging landscape for pharmaceutical, medtech, and clinical research organizations. With this as the context, Norstella recently held a recent roundtable discussion in London featuring several members of […] Read more
Infographic | Jun. 05, 2024

Obesity R&D in 2024 & beyond: Key considerations in an increasingly competitive landscape

Norstella empowers stakeholders involved in obesity drug development to make informed decisions based on trusted industry data and expert insights. This infographic uses some of those data and insights to demonstrate the various complex factors that continue to impact obesity R&D, assess expectations for future development in this space, and emphasize how Norstella serves as […] Read more
Article | May. 16, 2024

Why are clinical development success rates falling?

Likelihood of approval for new Phase I drugs is now just 6.7% Phase transition data from Citeline for the 10-year period between 2014ؘ and 2023 show that the average likelihood of approval (LOA) for a new Phase I drug is now just 6.7%. This has steadily fallen in each analysis to an all-time low. The […] Read more
Video | May. 03, 2024

Unlocking success in the evolving pharma landscape: Insights from Norstella’s Daniel Chancellor

Norstella’s Daniel Chancellor opines on the essential big picture dynamics in today’s pharma landscape. With clinical advances benefitting patients that had been previously overlooked, pharma companies are shifting how they build their pipelines and communicate value to payers. Deciding on the right strategies relies on having access to the best data, learning the lessons from […] Read more
Article | May. 03, 2024

The ADC market: Hot – or too hot to handle?

Antibody-drug conjugates (ADCs) are a unique class of drug compound, comprising a monoclonal antibody (mAb), a linker, and a cytotoxic payload. Together, these make it possible to target tumors with far greater specificity than with traditional forms of treatment. “This unique design enables ADCs to achieve ‘targeted chemotherapy’ and provides advantages over conventional chemotherapy and […] Read more
Article | Apr. 23, 2024

How women are transforming life sciences

Maureen Ladouceur is Norstella’s EVP and Chief Commercial Officer. She recently spoke with Andrea Charles, VP of Custom Content at Norstella, about her career in life sciences, women leading innovation in this space, and what major trends she expects for this industry. Highlights from their discussion are summarized below. A career focused on patient impact […] Read more
Article | Apr. 15, 2024

GLP-1: The 360° view

The GLP-1 agonist class of drugs, pioneered by Eli Lilly and Novo Nordisk, has become the biggest news story within the biopharma industry of the last couple of years. With tremendous clinical data supporting >20% weight loss and reduction in cardiovascular outcomes, there is seemingly no limit to the potential of these medicines. Analysts and […] Read more
Article | Apr. 11, 2024

Eight routes to patient diversity

Norstella helps clients achieve diversity in clinical trials while committing to it in its own practices. Andrew Warmington, manufacturing editor at Norstella, spoke to Fenwick Eckhardt, senior manager of clinical new product development at Norstella Diversity is a widely used term in many contexts and clinical trials are no exception. But what does the word […] Read more
Ebook | Mar. 29, 2024

Paving the way for women in life sciences

The ultimate success of the life sciences industry is highly dependent on a diverse workforce of pioneers, collaborators, and change-drivers, though there is still progress to be made with regard to gender equality in this field. Life sciences organizations are thus exploring ways to best prioritize diversity, including how to advocate for equality among leadership […] Read more
Article | Feb. 28, 2024

A new era for patient recruitment and retention in rare disease

Pharma and biotech organizations continue to prioritize the diversification of their pipelines to innovate more in areas of high and rare unmet need. In addition to delivering life-saving treatments to patients who have had historically limited therapeutic options, addressing high and rare unmet needs can lead to faster routes to market with accelerated regulatory pathways […] Read more
Article | Feb. 28, 2024

What private equity’s growing investment in urology practices means for oncology manufacturers

Over the past five years, private equity groups have slowly increased their acquisition of urology practices, increasing their footprint and influence in the urology channel. While many debate the impact of private equity on healthcare delivery and quality, the PE footprint across U.S. healthcare is expected to grow consistently over the next few years. Private […] Read more
Article | Jan. 23, 2024

Urology practices’ growing role in oncology: Three trends to watch

In 2024, urology practices continue to expand their role in the oncology treatment space, and proactive pharma companies are increasingly focusing on this channel. Historically, urology practices directed their patients to specialized oncology practices and academic care centers for treatment of advanced genitourinary (GU) cancers, such as prostate cancer or urothelial carcinoma. However, in recent […] Read more
Article | Dec. 19, 2023

What do you think was the single most consequential event or result in pharma/biopharma in 2023?

Certainly, the Inflation Reduction Act will continue to play out as it relates to pricing and reimbursements, as well as potential impacts to exclusivity. But putting aside regulatory impacts for a moment, the most consequential change I see is the democratization of AI. AI in and of itself has been put into practice by companies […] Read more
Article | Nov. 29, 2023

Worries and hopes for health care delivery in 2024

Industry experts from Norstella, whose data and technologies support decision making from R&D through to market access, shared their worries going into 2024. From less tolerance for failure as pressure mounts on pipelines to ongoing consequences of regulatory changes, such as the introduction of US Inflation Reduction Act, life sciences companies will face a number […] Read more
Article | Oct. 26, 2023

3 key challenges discussed at Cell & Gene Meeting on the Mesa

At the 2023 Cell & Gene Meeting on the Mesa earlier this month, senior executives and top decision-makers discussed commercialization challenges facing the cell and gene therapy sector. This year’s conference called out some of the biggest issues that the industry is facing. Leaders discussed challenges ranging from manufacturing scalability issues to gaps in Medicare […] Read more
Article | Oct. 25, 2023

6 step guide: Successfully navigating complexities of drug development

Not only is developing a new drug expensive, but an extraordinarily lengthy and complex process. In fact, some estimate that drug development can cost upwards of $2.8 billion and take 10-15 years. From the initial stages of drug discovery, clinical trials and regulatory approvals, to pre-and post-launch strategizing and commercialization, pharmaceutical companies face numerous obstacles […] Read more
Report | Jun. 27, 2023

How real-world evidence is impacting regulatory decision-making: A collection of 10 recent regulatory decisions based on RWE

Volume 3 Discover the power of real-world evidence (RWE) in shaping regulatory decisions through “How RWE is Impacting Regulatory Decision-Making.” Volume 3 of Panalgo’s popular use cases series reveals 10 recent instances where life sciences companies have not only invested in RWE but have successfully utilized it in their submissions to the FDA and other […] Read more
Article | Jun. 20, 2023

10 questions that oncology manufacturers should be asking about the Stark Law

Even though we knew it was coming, the end of the COVID public health emergency (PHE) on May 11, 2023, still took the healthcare industry by surprise. While the end of the PHE resulted in the rollback of many COVID-19 programs, it also changed the ways that Medicare patients can access oral therapies from community […] Read more
Article | Jun. 08, 2023

A 26-year journey to reach a complex rare disease diagnosis

Imagine: it’s Saturday, and you’re at your five-year-old’s soccer game on a beautiful spring day. As she runs down the field, you watch her collapse because her knee just dislocated. This is where Norstella’s Go To Market Director for Patient Engagement & Recruitment, Haley Quinn’s rare disease story starts. At the time of this first […] Read more
Article | May. 24, 2023

5 barriers to access for sickle cell disease gene therapies

Sickle cell disease (SCD) is a genetic blood disorder that affects the lives of 100,000 Americans1. SCD causes abnormal hemoglobin molecules in the red blood cells, resulting in cells forming in a crescent or sickle shape, which can block blood vessels and cause pain, organ damage, and other complications. This cellular-level disfunction is addressable with […] Read more
Article | Jan. 30, 2023

Using coverage and claims data provides pharma a view of payer and prescriber behavior

Insufficient return on investment due to an underperforming launch is a thought that makes any pharma manufacturer shudder. Considering that about half of all products launched over the last 15 years have underperformed pre-launch consensus forecasts by more than 20%, companies must proactively plan their near- and long-term strategies to ensure financial losses remain a […] Read more
Report | Aug. 15, 2022

How real-world evidence is impacting regulatory decision-making: A collection of 12 recent approvals based on RWE

Volume 1 From the new FDA framework to the urgency of COVID-19, recent events have dramatically accelerated the use of RWE in regulatory decision-making. Now, life sciences organizations are investing heavily in analytics to generate RWE for regulatory submission. Read more
Article | Jan. 23, 2023

Clinical pathways: What are they, and how do they affect access?

By Lindsay Lorenzen VP of Solution Consulting, Norstella Pharma manufacturers working within oncology, and a few other select fields, face a unique challenge when bringing their therapies to market: clinical pathways. According to MMIT Pulse Analytics data, roughly 62% of U.S. oncologists are currently exposed to a clinical pathway. And of those using pathways, adherence […] Read more
Article | Jan. 17, 2023

15 critical business questions keeping pharma leaders up at night

To ensure success in today’s evolving pharmaceutical marketplace, you need answers to critical business questions at each step of the drug development life cycle. Is your organization equipped to answer these burning questions? Business Development 1. Of all assets available, what asset has the highest potential and is most likely to give me the patient […] Read more
Article | Jan. 09, 2023

Norstella SMEs reflect on the biggest stories of 2022 and the industry trends to come

Now that 2023 is upon us, now’s the time to gather some key intel from the past year: What did we learn from some of the biggest stories in life sciences? And how can we apply those learnings in the year ahead? To gain some perspective, we tapped SMEs from across the Norstella brands to […] Read more
Article | Jan. 09, 2023

Improving market access: Are you making the most of real-world data?

By Lindsay Lorenzen VP of Solution Consulting, Norstella As drug and therapy innovation becomes more specialized and costs continue to rise, improving market access becomes more complicated. As the landscape evolves, pharma manufacturers must strategize accordingly to ensure a successful launch. Navigating the changing market access landscape is a common struggle for pharma manufacturers: One […] Read more
Article | Jan. 02, 2022

Breaking down the top three barriers to patient access

By Lindsay Lorenzen VP of Solution Consulting, Norstella Payers drive an increasingly large portion of the decision-making surrounding patient access. They determine how a drug is placed on formulary, what restrictions should exist, how and when patients qualify, etc., before patients can access a life-saving therapy or treatment. This means that pharma manufacturers who want […] Read more
Report | Jan. 23, 2023

How real-world evidence is impacting regulatory decision-making: 12 recent approvals based on RWE

Volume 2 Offering 12 new use cases of life sciences companies continuing to invest in RWD to advance product approvals before an FDA that is only becoming more accepting of RWE. Read more
Article | Sep. 08, 2022

Insights & innovators: A Q&A with Greg Norman and Katia Hannah from Dexcom

In our latest edition of our Insights & Innovators blog, we sit down with members of Dexcom’s HEOR team to discuss how they use analytics to generate evidence of efficacy and cost-effectiveness for their products. Read more
Article | Dec. 12, 2022

What the changing definition of patient access means for pharma manufacturers

By Lindsay Lorenzen VP of Solution Consulting, Norstella The shift away from blockbuster drugs has led the pharmaceutical industry toward more specialized drugs and therapeutic areas for rare diseases, oncology and gene therapy. This wave of specialized, niche therapies has not only necessitated a more in-depth approach to commercialization but also led to increasingly complex […] Read more
Article | Dec. 09, 2022

Health insurance startup CEOs’ sky-high compensation figures are deceiving

In AIS Health’s annual roundup of health insurer executive compensation data, four newly public startup insurers stand out because their CEOs’ total compensation in 2021 easily outstrips that of chief executives at major firms like UnitedHealth Group and Cigna Corp. However, experts tell AIS Health that the startups’ filings with federal regulators paint an unintentionally […] Read more
Article | Nov. 15, 2022

Pipeline to Patient: Norstella delivers answers you can act on at every point of the drug development lifecycle

Pharma has questions throughout the life cycle. Norstella delivers answers you can act on at every point, from drug development through commercialization. Here are some critical questions you ask, and we answer below. Pre-clinical • What therapy areas lack effective treatments? • Which drugs should we invest in from the outset? • How many patients could we reach […] Read more
Article | Dec. 21, 2021

Market access speed is the next critical differentiator for pharma manufacturers

With the cost of healthcare and drug discovery continuing to rise and value-based contracting gaining traction, demonstrating a product’s economic value compared to existing competitor products is more important than ever. Drugs today need to be reimbursable, not just approvable, writes MMIT’s Dinesh Kabaleeswaran in an article for PharmExec. Read more
Article | Sep. 15, 2021

RWE: Supporting regulatory submissions with real-world evidence

When submitting RWE, it is crucial for life sciences organizations to not only feel confident in the data they provide, but also that it will be accepted by regulatory reviewers, writes Panalgo’s Tiffany Siu Woodworth. The main question these companies must ask themselves is, how can we trust the evidence we are providing? Read more
Report | Jul. 30, 2021

Evaluate pharma world preview 2021: Outlook to 2026

Evaluate’s comprehensive report tracks the expected performance of the biopharma industry between now and 2026, based on Evaluate Pharma’s coverage of the world’s leading pharmaceutical and biotech companies. Read more
Read More

Events

Work with us

Join our mission

We’re looking for agile, growth-oriented team players who are passionate about client success and helping clients bring life-saving therapies to market quicker—and help patients in need.

Work with us

Get in Touch

Let's connect

Have questions about Norstella or its brands? Or do you want to know more about how to solve your challenges at each stage of the drug life cycle?

We want to hear from you